The Cannabix Marijuana Breathalyzer system is being developed to give law enforcement and employers a tool to enforce public safety

VANCOUVER, British Columbia, April 17, 2019 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to report that recent characterization work with Cannabix’s FAIMS (field asymmetric waveform ion mobility spectrometry) THC detection device with human subjects has shown the ability to consistently discriminate unwanted ions from complex human breath background matrices allowing for THC (∆9-tetrahydrocannabinol) detection.  In particular, recent testing with updated FAIMS cell geometries has shown the ability to consistently supress several compounds that are commonly found in breath like nicotine, garlic, onion, meats, ethanol, and volatile flavorants such as methyl salicylate and menthol (commonly found in gum) allowing for discrimination and mobility of THC in exhaled breath.

The Company is also pleased to report that engineers have developed a new atmospheric pressure chemical ionization source that provides significantly improved ion control in terms of intensity, stability, and focusing. 
Early testing with high concentrations of a range of interferents collected from the breath of human subjects did not affect the sensitivity of the FAIMS device. These include complex matrices such as tomato juice and mouthwash. Testing with various common high salt and high sugar content electrolyte drinks was also conducted to determine if adduct ions would form that could interfere with the device, thus far none of these have done so.

Cannabix scientists have been focusing their efforts to complete characterization of FAIMS with various possible breath and environmental contaminants and are nearing completion of this phase of development. The Company then plans to initiate third-party testing and piloting of the device. The Company has received interest in piloting from both U.S. and Canadian law enforcement groups as well as other organizations that drug test their employees.

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable hand-held tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many global jurisdictions. Cannabix is working to develop drug-testing devices that will detect THC- the psychoactive component of marijuana that causes intoxication- using breath samples. In particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects previous usage from days or even weeks earlier. The devices will also be useful for other practical applications such as testing employees in the workplace where impairment by THC can be hazardous.

We seek Safe Harbor.  

On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities.  The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.